These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The FDA Approves Aducanumab for Alzheimer's Disease, Raising Important Scientific Questions1. de la Torre JC; Gonzalez-Lima F J Alzheimers Dis; 2021; 82(3):881-882. PubMed ID: 34250943 [No Abstract] [Full Text] [Related]
24. The Failure of Solanezumab - How the FDA Saved Taxpayers Billions. Sacks CA; Avorn J; Kesselheim AS N Engl J Med; 2017 May; 376(18):1706-1708. PubMed ID: 28467878 [No Abstract] [Full Text] [Related]
25. Aducanumab and the Business of Alzheimer Disease-Some Choice. Karlawish J JAMA Neurol; 2021 Nov; 78(11):1303-1304. PubMed ID: 34410302 [No Abstract] [Full Text] [Related]
26. Update: FDA approval of Biogen's aducanumab. Hollmann P Geriatr Nurs; 2022; 43():318-319. PubMed ID: 34996638 [No Abstract] [Full Text] [Related]
28. Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered. Rubin R JAMA; 2021 Aug; 326(6):469-472. PubMed ID: 34287610 [No Abstract] [Full Text] [Related]
29. What the Aducanumab Approval Reveals About Alzheimer Disease Research. Manly JJ; Glymour MM JAMA Neurol; 2021 Nov; 78(11):1305-1306. PubMed ID: 34605885 [No Abstract] [Full Text] [Related]
30. A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab. Emanuel EJ JAMA; 2021 Oct; 326(14):1367-1368. PubMed ID: 34554184 [No Abstract] [Full Text] [Related]
31. Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease. Zissimopoulos J; Jacobson M; Chen Y; Borson S JAMA Netw Open; 2022 Feb; 5(2):e2148355. PubMed ID: 35157058 [TBL] [Abstract][Full Text] [Related]
32. Does the FDA-approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia? Gleason A; Ayton S; Bush AI Med J Aust; 2022 Mar; 216(4):172-174. PubMed ID: 35141902 [No Abstract] [Full Text] [Related]
33. What to Know About the Alzheimer Drug Aducanumab (Aduhelm). Woloshin S; Kesselheim AS JAMA Intern Med; 2022 Aug; 182(8):892. PubMed ID: 35666531 [No Abstract] [Full Text] [Related]
34. Aducanumab for Alzheimer's disease: A regulatory perspective. Nisticò R; Borg JJ Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility. Alexander GC; Emerson S; Kesselheim AS JAMA; 2021 May; 325(17):1717-1718. PubMed ID: 33783469 [No Abstract] [Full Text] [Related]
36. Of education and public policy: Aducanumab. Lundebjerg NE; Hollmann PA; Supiano MA J Am Geriatr Soc; 2022 Jan; 70(1):81-84. PubMed ID: 34674219 [No Abstract] [Full Text] [Related]
37. Ignoring the Experts: Implications of the FDA's Aduhelm Approval. Maulden A Am J Law Med; 2022 Mar; 48(1):108-133. PubMed ID: 35815585 [TBL] [Abstract][Full Text] [Related]
39. Making the Case for Accelerated Withdrawal of Aducanumab. Whitehouse P; Gandy S; Saini V; George DR; Larson EB; Alexander GC; Avorn J; Brownlee S; Camp C; Chertkow H; Fugh-Berman A; Howard R; Kesselheim A; Langa KM; Perry G; Richard E; Schneider L J Alzheimers Dis; 2022; 87(3):1003-1007. PubMed ID: 35404287 [TBL] [Abstract][Full Text] [Related]